The STAR*D study: Treating depression in the real world

Cleveland Clinic Journal of Medicine

Volumn 75, Issue 1, 2008, Pages 57-66

  Gaynes, Bradley N ^a   Rush, A John ^b   Trivedi, Madhukar H ^b   Wisniewski, Stephen R ^c   Spencer, Donald ^a   Fava, Maurizio ^d  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM;

ALGORITHM; CLINICAL TRIAL; DEPRESSION; DISEASE COURSE; HUMAN; REVIEW; TREATMENT OUTCOME;

ALGORITHMS; ANTIDEPRESSIVE AGENTS; CITALOPRAM; CLINICAL TRIALS AS TOPIC; DEPRESSION; DISEASE PROGRESSION; HUMANS; TREATMENT OUTCOME;

EID: 39749159144     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.75.1.57     Document Type: Article

References (43)

1. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289:3095-3105.
2. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349:1436-1442.
3. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1947; 349:1498-1504.
4. Zimmerman M, Chelminski I, Posternak MA. Generalizability of anti-depressant efficacy trials: differences between depressed psychiatric outpatients who would or would not qualify for an efficacy trial. Am J Psychiatry 2005; 162:1370-1372.
5. Rothwell PM. External validity of randomised controlled trials: to whom do the results of this trial apply? Lancet 2005; 365:82-93.
6. Depression Guideline Panel. Depression in primary care: Volume 1, diagnosis and detection. AHCPR publication No. 93-0550. Rockville, MD: U.S. Department of Health and Human Services, Public Health. Service, Agency for Health Care Policy and Research; 1993.
7. Frank E, Karp J, Rush A. Efficacy of treatments for major depression. Psychopharmacol Bull 1993; 29:457-475.
8. Depression Guideline Panel. Depression in primary care: Volume 2, Treatment of major depression. AHCPR publication No. 93-0550. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research; 1993.
9. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996; 19:179-200.
10. Jarrett RB, Rush A. Short-term psychotherapy of depressive disorders: current status and future directions. Psychiatry: Interpers Biol Process 1994; 57:115-132.
11. American Psychiatric Association. Practice guideline for the treatment of patients with major depression (revision). Am J Psychiatry 2000; 157(suppl 4):1-45.
12. Dunner DL, Rush AJ, Russell JM, et al. Prospective, long-term, multi-center study of the naturalistic outcomes of patients with treatment-resistant depression. J Clin Psychiatry 2006; 67:688-695.
13. Fava M, Rush A, Trivedi M, et al. Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Psychiatr Clin North Am 2003; 26:457-494,
14. Gaynes B, Davis L. Rush A, Trivedi M, Fava M, Wisniewski S. The aims and design of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study. Prim Psychiatry 2005; 12:36-41.
15. Rush A, Fava M, Wisniewski S, et al. Sequenced Treatment Alternatives to Relieve Depression (STAR*D): rationale and design. Control Clin Trials 2004; 25:119-142.
16. Stafford RS, Ausiello JC, Misra B, Saglam D. National Patterns of Depression Treatment in Primary Care. Prim Care Companion J Clin Psychiatry 2000; 2:211-216.
17. Regier D, Narrow W, Rae D, Mandersheid R, Locke B, Goodwin F. The de facto US mental and addictive disorders service system: epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry 1993; 50:85-94.
18. Pincus H, Tanielian T, Marcus S, et al. Prescribing trends in psychotropic medications: primary care, psychiatry, and other medical specialities. JAMA 1998; 279:526-531.
19. Vuorilehto M, Melartin T, Isometsa E. Depressive disorders in primary care: recurrent, chronic, and co-morbid. Psychol Med 2005; 35:673-682.
20. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
21. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-61.
22. Wisniewski SR, Rush AJ, Balasubramani GK, Trivedi MH, Nierenberg AA for the STAR*D Investigators. Self-rated global measure of the frequency, intensity, and burden of side effects. J Psychiatric Pract 2006; 12:71-79.
23. Rush AJ, Bernstein IH, Trivedi MH, et al. An evaluation of the Quick Inventory of Depressive Symptomatology and the Hamilton Rating Scale for Depression: a Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial report. Biol Psychiatry 2006; 59:493-501.
24. Trivedi MH, Rush AJ, Gaynes BN, et al. Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR*D measurement-based care. Neuropsychopharmacology 2007/04/04/ online 2007.
25. Kawamoto K, Houlihan CA, Balas EA, Lobach DF. Improving clinical practice using clinical decision support systems: a systematic review of trials to identify features critical to success. BMJ 2005, 330.765 e-pub March 14 2005.
26. Lavori P, Rush A, Wisniewski S, et al. Strengthening clinical effectiveness trials: equipoise-stratified randomization. Biol Psychiatry 2001; 50:792-801.
27. Gaynes BN, Rush AJ, Trivedi MH, et al. Major depression symptoms in primary care and psychiatric care settings: a cross-sectional analysis. Ann Fam Med 2007; 5:126-134.
28. Gaynes BN, Rush AJ, Trived M, et al. A direct comparison of presenting characteristics of depressed outpatients from primary vs. specialty care settings: preliminary findings from the STAR*D clinical trial. Gen Hosp Psychiatry 2005; 27:87-96.
29. Sullivan PW, Valuck R, Saseen J, MacFall HM. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs 2004; 18:911-932.
30. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163:28-40.
31. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006; 354:1231-1242.
32. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006; 354:1243-1252.
33. Wisniewski SR, Fava M, Trivedi MH, et al. Acceptability of second-step treatments to depressed outpatients: a STAR*D report. Am J Psychiatry 2007; 164:753-160.
34. Thase ME, Friedman ES, Biggs MM, et al. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry 2007; 164:739-752.
35. Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 2006; 163:1161-1172.
36. Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T3 augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006; 163:1519-1530.
37. Bschor T, Lewitzka U, Sasse J, Adli M, Koberle U, Bauer M. Lithium augmentation in treatment-resistant depression: clinical evidence, serotonergic and endocrine mechanisms. Pharmacopsychiatry 2003; 36(suppl 3):S230-S234.
38. Freeman MP, Freeman SA. Lithium: clinical considerations in internal medicine. Am J Med 2006; 119:478-481.
39. Aronson R, Offman HJ, Joffe RT, Naylor CD. Triiodothyronine augmentation in the treatment of refractory depression. A metaanalysis. Arch Gen Psychiaitry 1996; 53:842-848.
40. McGrath PJ, Stewart JW, Fava M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry 2006; 163:1531-1541.
41. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163:1905-1917.
42. Gartlehner G, Hansen R, Thieda P, et al. Comparative Effectiveness of Second-generation Antidepressants in the Pharmacologic Treatment of Depression. Agency for Healthcare Research and Quality. http://effectivehealthcare.ahrq.gov/reports/topic.cfm.?topic=8&sid= 39&rType=3. Accessed December 12, 2007.
43. Das AK, Olfson M, Gameroff MJ, et al. Screening for bipolar disorder in a primary care practice. JAMA 2005; 293:956-963.